Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

NCT04248829 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

393

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Lazertinib 240 mg/160 mg
DRUG: Gefitinib 250 mg
DRUG: Lazertinib-matching placebo 240 mg/160 mg
DRUG: Gefitinib-matching placebo 250 mg

Sponsor

Yuhan Corporation